Asan Mohamed Faizal, Castelino Renita Lorina, Babu Subhas G, Rao Kumuda, Pandita Vaibhav
Department of Oral Medicine and Radiology, Nitte (Deemed to be University), AB Shetty Memorial Institute of Dental Sciences, Mangalore, Karnataka, India.
Asia Pac J Oncol Nurs. 2021 Oct 4;8(6):604-609. doi: 10.4103/apjon.apjon-2136. eCollection 2021 Nov-Dec.
Recent advent of immune checkpoint inhibitors (ICIs) have made significant improvement in the treatment outcome of cancer patients. They are also known to increase the overall survival in many malignancies. They target key immune checkpoints, acting on the cytotoxic T-lymphocyte antigen-4, programmed death-1 (PD-1), and PD-1 ligand 1 pathways. ICIs are effective in cancer therapy, but also possess various adverse effects that are termed together as immune-related adverse events (irAEs). Information focusing only on the oral reactions of irAEs is scanty in the literature. Therefore, we performed a computerized database search in PubMed and Google Scholar to identify and collect data regarding the oral adverse effects of ICIs. The early recognition of oral irAEs and appropriative intervention may help in improving the quality of life in patients. This paper presents a brief review of oral irAEs and their management.
免疫检查点抑制剂（ICI）的近期问世使癌症患者的治疗结果有了显著改善。众所周知，它们还能提高许多恶性肿瘤患者的总生存率。它们靶向关键的免疫检查点，作用于细胞毒性T淋巴细胞抗原4、程序性死亡蛋白1（PD-1）和PD-1配体1通路。ICI在癌症治疗中有效，但也具有各种不良反应，这些不良反应统称为免疫相关不良事件（irAE）。文献中仅关注irAE口腔反应的信息很少。因此，我们在PubMed和谷歌学术上进行了计算机化数据库搜索，以识别和收集有关ICI口腔不良反应的数据。早期识别口腔irAE并进行适当干预可能有助于提高患者的生活质量。本文简要综述了口腔irAE及其管理。
